Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report

Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report

Source: 
Endpoints
snippet: 

With rumors swirling about a potential buyout of biotech Acceleron and its lead PAH drug sotatercept, market watchers have been keeping close tabs on industry movers and shakers due up for an expensive bolt-on. According to a new report, it appears Merck may be the one.